- Home
- TCRX vs DALN Comparison
TCRX vs DALN Comparison
Compare TCRX & DALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- DALN
- Stock Information
- Founded
- TCRX 2018
- DALN 1954
- Country
- TCRX United States
- DALN United States
- Employees
- TCRX N/A
- DALN N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- DALN Newspapers/Magazines
- Sector
- TCRX Health Care
- DALN Consumer Discretionary
- Exchange
- TCRX Nasdaq
- DALN Nasdaq
- Market Cap
- TCRX 91.7M
- DALN 79.8M
- IPO Year
- TCRX 2021
- DALN 2008
- Fundamental
- Price
- TCRX $1.91
- DALN $14.85
- Analyst Decision
- TCRX Strong Buy
- DALN
- Analyst Count
- TCRX 5
- DALN 0
- Target Price
- TCRX $9.40
- DALN N/A
- AVG Volume (30 Days)
- TCRX 208.8K
- DALN 73.6K
- Earning Date
- TCRX 08-12-2025
- DALN 07-30-2025
- Dividend Yield
- TCRX N/A
- DALN N/A
- EPS Growth
- TCRX N/A
- DALN N/A
- EPS
- TCRX N/A
- DALN N/A
- Revenue
- TCRX $6,961,000.00
- DALN $121,119,000.00
- Revenue This Year
- TCRX $255.18
- DALN N/A
- Revenue Next Year
- TCRX N/A
- DALN N/A
- P/E Ratio
- TCRX N/A
- DALN N/A
- Revenue Growth
- TCRX N/A
- DALN N/A
- 52 Week Low
- TCRX $1.02
- DALN $3.66
- 52 Week High
- TCRX $6.23
- DALN $16.10
- Technical
- Relative Strength Index (RSI)
- TCRX 59.09
- DALN 68.31
- Support Level
- TCRX $1.73
- DALN $14.83
- Resistance Level
- TCRX $1.95
- DALN $14.95
- Average True Range (ATR)
- TCRX 0.12
- DALN 0.13
- MACD
- TCRX 0.01
- DALN -0.21
- Stochastic Oscillator
- TCRX 84.85
- DALN 4.65
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company. It operates The Dallas Morning News (dallasnews.com), Texas' newspaper. These operations generate revenue from advertising sales within the company's newspaper and digital platforms, subscriptions and retail sales of its newspaper, and commercial printing and distribution services predominantly related to national newspapers. In addition to traditional print and digital advertising, the company has a full-service agency, Medium Giant, offering businesses comprehensive, strategic, and creative marketing solutions. The company's two reportable segments are TDMN and Agency. Maximum revenue is derived from the TDMN segment, which comprises its traditional print business. The firm's customer base is concentrated in North Texas.